Chemomab Therapeutics Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Chemomab Therapeutics Ltd. generated cash of -$23,611,000, which is less than the previous year. Cash used in financing activities reached the amount of $3,504,000 last year. Net change in cash is therefore -$4,228,000.
Cash Flow
| 2015 | -7.38M | 1.11M | 4.47M |
|---|---|---|---|
| 2017 | -8.51M | -34K | 5.24M |
| 2018 | -8.51M | -34K | 5.24M |
| 2019 | -16.51M | -95.30K | 26.70M |
| 2020 | -5.24M | -62K | 4.75M |
| 2021 | -12.37M | -45.18M | 61.07M |
| 2022 | -20.37M | 19.53M | -808K |
| 2023 | -23.61M | 15.87M | 3.50M |
CMMB Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.59M | 15.24M | 11.72M | 12.28M | 7.51M | 0 | 4.56M | 3.99M |
Operating activities | ||||||||
Net income | -24.22M | -27.64M | -12.47M | -5.95M | -27.21M | 0 | -9.80M | -7.50M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 66.82K | 58K | 34K | 24K | 281.90K | 0 | 51K | 26.25K |
Stock-based compensation expense | 1.49M | 3.21M | 2.01M | 130K | 135K | 0 | 0 | 0 |
| Deferred income tax benefit | 1.49M | 3.21M | 2.01M | 130K | 135K | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 903 | -64 | -2.05K | -99 | 2.31M | 0 | 204K | -568.30K |
Inventories | 0 | 64 | 2.05K | 99 | 0 | 0 | 0 | 0 |
Accounts payable | -1.16M | 352K | 1.17M | 68K | 1.07M | 0 | 44K | 423.14K |
Cash generated by operating activities | -23.61M | -20.37M | -12.37M | -5.24M | -16.51M | -8.51M | -8.51M | -7.38M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | -45.95M | -24K | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3K | -68K | -239K | -38K | -95.30K | 0 | -34K | -87.25K |
Acquisitions Net | 0 | 0 | 0 | 136K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 15.87M | 19.53M | -45.18M | -62K | -95.30K | -34K | -34K | 1.11M |
Financing activities | ||||||||
Common Stock Issued | 3.50M | 267K | 58.63M | 3.5M | 26.70M | 0 | 5.24M | 4.58M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -1.21M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 3.50M | -808K | 61.07M | 4.75M | 26.70M | 5.24M | 5.24M | 4.47M |
Net Change In Cash | -4.22M | -1.64M | 3.51M | -554K | 10.05M | -3.30M | -3.10M | -1.78M |
Cash at end of period | 9.36M | 13.59M | 15.24M | 11.72M | 17.57M | -3.30M | 1.45M | 2.20M |
| Data source | Data source | Data source | Data source | Data source | Data source |